Have you been diagnosed with Monoclonal Gammopathy of Undetermined Significance? Do your feet hurt aka nerve pain? Please scroll down the page, post a question or comment and I will reply ASAP.
Hi. My name is David Emerson. I am a long-term survivor of multiple myeloma (MM) and a MM cancer coach. My guess is that you have been wondering about both your diagnosis of monoclonal gammopathy of underdetermined significance as well as a symptom of MGUS called Peripheral Neuropathy (PN).
Suffice to say that Monoclonal Gammopathy of Undetermined Significance is a little known and less-well understood blood disorder. It is not cancer. It is “pre-cancer.” And yes, patients can sometimes experience nerve pain. Yes, this blood disorder can lead to a diagnosis of Multiple Myeloma but I’ll get to that later.
Your challenge is that conventional oncology does not treat blood disorders. Your oncologist may have told you to “watch and wait” regarding your MGUS. Your first step then is to read the studies linked and excerpted below in an effort to understand your condition and then communicate with me about possible evidence-based, non-conventional therapies.
I have remained in complete remission from MM since 1999 by living an evidence-based, non-toxic, anti-MM lifestyle through nutrition, supplementation, bone health, detoxification, and mind-body therapies. I’m telling you this not to introduce you to the virtues of therapies like acupuncture, essential oils or yoga, I am telling you this in an effort to explain how important non-FDA approved therapies can be to MM and MGUS patients.
To learn more about the evidence-based protocols you can follow to prevent your Pre-Myeloma from becoming Multiple Myeloma, please watch the short video below:
” Four statistically significant differences set IgM-MGUS neuropathies apart from IgG-MGUS and IgA-MGUS neuropathies: (1) higher frequency of sensory loss and ataxia, (2) higher frequency of nerve conduction abnormality–10 attributes were significantly worse (none were significantly better), (3) higher frequency of dispersion of the compound muscle action potential, and (4) higher frequency of IgM-MGUS in the MGUS neuropathy cohort that is characteristic of MGUS without neuropathy seen at our institution or that is encountered in epidemiological surveys…”
“We evaluated the clinical characteristics and electromyographic features of 39 patients with monoclonal gammopathy of undetermined significance (MGUS) and neuropathy…
Comparing IgM-MGUS and IgG-MGUS neuropathies, we found the following differences: (1) There was a statistically significant higher frequency of sensory loss in the IgM group. (2) Nine attributes of nerve conduction abnormality were statistically worse in the IgM group, with slowing of conduction velocities and prolonged distal latencies. (3) The frequency of monoclonal IgM was overrepresented in the MGUS neuropathy group…”
If you do not want to “watch and wait” to see if your MGUS progresses to Multiple Myeloma click the blue button below to watch a FREE webinar about managing MGUS to prevent Multiple Myeloma:
Learn about MGUS therapies such as: